Log In
Print
BCIQ
Print
Print this Print this
 

tildrakizumab (MK-3222) (formerly SCH 900222)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionAnti-IL-23 antibody
Molecular Target Interleukin-23 (IL-23)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationPsoriasis
Indication DetailsTreat moderate to severe chronic plaque psoriasis
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today